- Patients who develop anaemia may need blood transfusions. Dose adjustment or interruption may also be considered in patients who develop anaemia. Starting dose of Jakavi in PV patients: 10 mg twice daily 1 Starting dose of Jakavi in MF...Twitter Linkedin Facebook Pinterest Google plus
CAR-T talks: cryopreservation, key element for success
As living drugs, chimeric antigen receptor T-cells (CAR-T cells) come with unique manufacturing and commercialisation challenges. In this respect, the use of fresh leukapheresis material was rapidly recognised as an important bottleneck in...
Twitter Linkedin Facebook Pinterest Google plusEfficacy
The efficacy of Tafinlar ® (dabrafenib) + Mekinist ® (trametinib) has been investigated in various studies. Read more below about some important results from these studies.
Adjuvant treatment of stage III melanoma...Twitter Linkedin Facebook Pinterest Google plusEfficacy
SOLAR-1:
Pivotal randomized, double-blind, placebo-controlled, multicenter phase 3 trial in HR+/HER2-aBC 1 . A total of 572 patients were enrolled in the trial, including 341 patients with a PIK3CA mutation 1...
Twitter Linkedin Facebook Pinterest Google plusSafety
Predictable, manageable and reversible side effects while maintaining quality of life 6
As with any medication, side effects may occur when using the combination therapy Tafinlar® (dabrafenib) and Mekinist® (trametinib). The side...
Twitter Linkedin Facebook Pinterest Google plusCAR-T talks: bridging therapy during CAR-T manufacturing
Patients referred for CAR-T therapy have active relapsed/refractory disease and are therefore at high risk of disease progression during the CAR-T manufacturing. In order to prevent clinically significant disease progression during this...
Twitter Linkedin Facebook Pinterest Google plusCAR-T talks: Tisagenlecleucel: a new potentially curative treatment option for patients with relapsed/refractory follicular lymphoma
While follicular lymphoma (FL) is an indolent form of non-Hodgkin lymphoma that is generally associated with long remissions, the disease remains incurable and for patients with relapsed/refractory (r/r) FL the prognosis is dismal. The recent...
Twitter Linkedin Facebook Pinterest Google plusProgram: The Academy
PROGRAM 2020: DATE TOPIC SPEAKERS 29 Sep 2020 20h-21h How to go back to business after COVID-19 and how to prepare your hospital for a second wave? The CEO’s vision...Twitter Linkedin Facebook Pinterest Google plus